Skip to main content
Erschienen in: Current Cardiology Reports 9/2022

29.06.2022 | Valvular Heart Disease (TL Kiefer, Section Editor)

Update on Minimalist TAVR Care Pathways: Approaches to Care in 2022

verfasst von: Mariem A. Sawan, Avery E. Calhoun, Kendra J. Grubb, Chandan M. Devireddy

Erschienen in: Current Cardiology Reports | Ausgabe 9/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review summarizes current data supporting a minimalist TAVR approach and identifies the need for additional study to optimize TAVR care. The authors discuss future directions of the TAVR landscape and how this necessitates evolution of minimalist care pathways.

Recent Findings

Transcatheter aortic valve replacement (TAVR) has become a mainstay in the treatment of aortic stenosis since the initial procedure in 2002. Recently, attention has shifted to TAVR optimization and the minimalist approach with a focus on minimizing procedural sedation, protocolization of perioperative management, and prioritization on early discharge. This approach has been shown to be safe and reduce procedure time, length of stay, and overall cost for hospital systems.

Summary

The minimalist care pathway avoids general anesthesia, shortens procedure time and length of stay, and reduces cost without changing mortality or readmission rates at 30 days. A variety of protocols have been proposed without a clear consensus on specific components or patient eligibility. There is a continued need for data regarding patient risk stratification, valve selection, and discharge strategy as TAVR becomes increasingly common.
Literatur
4.
Zurück zum Zitat Sammour Y, Kerrigan J, Banerjee K, Gajulapalli RD, Lak H, Chawla S, et al. Comparing outcomes of general anesthesia and monitored anesthesia care during transcatheter aortic valve replacement: The Cleveland Clinic Foundation experience. Catheter Cardiovasc Interv. 2021;98:E436–43. https://doi.org/10.1002/ccd.29496.CrossRefPubMed Sammour Y, Kerrigan J, Banerjee K, Gajulapalli RD, Lak H, Chawla S, et al. Comparing outcomes of general anesthesia and monitored anesthesia care during transcatheter aortic valve replacement: The Cleveland Clinic Foundation experience. Catheter Cardiovasc Interv. 2021;98:E436–43. https://​doi.​org/​10.​1002/​ccd.​29496.CrossRefPubMed
5.
Zurück zum Zitat Hosoba S, Yamamoto M, Shioda K, Sago M, Koyama Y, Shimura T, et al. Safety and efficacy of minimalist approach in transfemoral transcatheter aortic valve replacement: insights from the Optimized transCathEter vAlvular interventioN-Transcatheter Aortic Valve Implantation (OCEAN-TAVI) registry. Interact Cardiovasc Thorac Surg. 2018;26:420–4. https://doi.org/10.1093/icvts/ivx355.CrossRefPubMed Hosoba S, Yamamoto M, Shioda K, Sago M, Koyama Y, Shimura T, et al. Safety and efficacy of minimalist approach in transfemoral transcatheter aortic valve replacement: insights from the Optimized transCathEter vAlvular interventioN-Transcatheter Aortic Valve Implantation (OCEAN-TAVI) registry. Interact Cardiovasc Thorac Surg. 2018;26:420–4. https://​doi.​org/​10.​1093/​icvts/​ivx355.CrossRefPubMed
6.
8.
10.
Zurück zum Zitat •• Wood DA, Lauck SB, Cairns JA, Humphries KH, Cook R, Welsh R, et al. The Vancouver 3M (Multidisciplinary, Multimodality, But Minimalist) Clinical Pathway Facilitates Safe Next-Day Discharge Home at Low-, Medium-, and High-Volume Transfemoral Transcatheter Aortic Valve Replacement Centers: The 3M TAVR Study. JACC Cardiovasc Interv. 2019;12:459–469. https://doi.org/10.1016/j.jcin.2018.12.020. This prospective multicenter study demonstrated the feasibility and safety of a comprehensive minimalist approach with next-day discharge. •• Wood DA, Lauck SB, Cairns JA, Humphries KH, Cook R, Welsh R, et al. The Vancouver 3M (Multidisciplinary, Multimodality, But Minimalist) Clinical Pathway Facilitates Safe Next-Day Discharge Home at Low-, Medium-, and High-Volume Transfemoral Transcatheter Aortic Valve Replacement Centers: The 3M TAVR Study. JACC Cardiovasc Interv. 2019;12:459–469. https://​doi.​org/​10.​1016/​j.​jcin.​2018.​12.​020. This prospective multicenter study demonstrated the feasibility and safety of a comprehensive minimalist approach with next-day discharge.
13.
15.
Zurück zum Zitat •• Barker M, Sathananthan J, Perdoncin E, Devireddy C, Keegan P, Grubb K, et al. Same-Day Discharge Post-Transcatheter Aortic Valve Replacement During the COVID-19 Pandemic: The Multicenter PROTECT TAVR Study. JACC Cardiovasc Interv. 2022;15:590–598. https://doi.org/10.1016/j.jcin.2021.12.046. Findings from this international prospective study demonstrated that same-day discharge post TAVR is safe in selected patients and showed similar rates of readmission compared to traditional TAVR. •• Barker M, Sathananthan J, Perdoncin E, Devireddy C, Keegan P, Grubb K, et al. Same-Day Discharge Post-Transcatheter Aortic Valve Replacement During the COVID-19 Pandemic: The Multicenter PROTECT TAVR Study. JACC Cardiovasc Interv. 2022;15:590–598. https://​doi.​org/​10.​1016/​j.​jcin.​2021.​12.​046. Findings from this international prospective study demonstrated that same-day discharge post TAVR is safe in selected patients and showed similar rates of readmission compared to traditional TAVR.
16.
Zurück zum Zitat Kasel AM, Cassese S, Bleiziffer S, et al. Standardized imaging for aortic annular sizing: implications for transcatheter valve selection. JACC Cardiovasc Imaging. 2013;6:249–62.CrossRef Kasel AM, Cassese S, Bleiziffer S, et al. Standardized imaging for aortic annular sizing: implications for transcatheter valve selection. JACC Cardiovasc Imaging. 2013;6:249–62.CrossRef
17.
Zurück zum Zitat Hahn RT, Nicoara A, Kapadia S, Svensson L, Martin R. Echocardiographic imaging for transcatheter aortic valve replacement. J Am Soc Echocardiogr. 2018;31:405–33.CrossRef Hahn RT, Nicoara A, Kapadia S, Svensson L, Martin R. Echocardiographic imaging for transcatheter aortic valve replacement. J Am Soc Echocardiogr. 2018;31:405–33.CrossRef
21.
Zurück zum Zitat Lateef N, Khan MS, Deo SV, Yamani N, Riaz H, Virk HUH, et al. Meta-Analysis Comparing Outcomes in Patients Undergoing Transcatheter Aortic Valve Implantation With Versus Without Percutaneous Coronary Intervention. Am J Cardiol. 2019;124:1757–64.CrossRef Lateef N, Khan MS, Deo SV, Yamani N, Riaz H, Virk HUH, et al. Meta-Analysis Comparing Outcomes in Patients Undergoing Transcatheter Aortic Valve Implantation With Versus Without Percutaneous Coronary Intervention. Am J Cardiol. 2019;124:1757–64.CrossRef
22.
Zurück zum Zitat Patterson T, Clayton T, Dodd M, Khawaja Z, Morice MC, Wilson K, et al. ACTIVATION Trial Investigators. ACTIVATION (PercutAneous Coronary inTervention prIor to transcatheter aortic VAlve implantaTION): A Randomized Clinical Trial. JACC Cardiovasc Interv. 2021;14:1965–1974. https://doi.org/10.1016/j.jcin.2021.06.041. Patterson T, Clayton T, Dodd M, Khawaja Z, Morice MC, Wilson K, et al. ACTIVATION Trial Investigators. ACTIVATION (PercutAneous Coronary inTervention prIor to transcatheter aortic VAlve implantaTION): A Randomized Clinical Trial. JACC Cardiovasc Interv. 2021;14:1965–1974. https://​doi.​org/​10.​1016/​j.​jcin.​2021.​06.​041.
23.
Zurück zum Zitat Thiele H, Kurz T, Feistritzer HJ, Stachel G, Hartung P, Eitel I, et al. Comparison of newer generation self-expandable vs. balloon-expandable valves in transcatheter aortic valve implantation: the randomized SOLVE-TAVI trial. Eur Heart J. 2020;41:1890–1899. https://doi.org/10.1093/eurheartj/ehaa036. Thiele H, Kurz T, Feistritzer HJ, Stachel G, Hartung P, Eitel I, et al. Comparison of newer generation self-expandable vs. balloon-expandable valves in transcatheter aortic valve implantation: the randomized SOLVE-TAVI trial. Eur Heart J. 2020;41:1890–1899. https://​doi.​org/​10.​1093/​eurheartj/​ehaa036.
25.
Zurück zum Zitat Abdel-Wahab M, Landt M, Neumann FJ, Massberg S, Frerker C, Kurz T, et al. CHOICE Investigators. 5-Year Outcomes After TAVR With Balloon-Expandable Versus Self-Expanding Valves: Results From the CHOICE Randomized Clinical Trial. JACC Cardiovasc Interv. 2020;13:1071–1082. https://doi.org/10.1016/j.jcin.2019.12.026. Abdel-Wahab M, Landt M, Neumann FJ, Massberg S, Frerker C, Kurz T, et al. CHOICE Investigators. 5-Year Outcomes After TAVR With Balloon-Expandable Versus Self-Expanding Valves: Results From the CHOICE Randomized Clinical Trial. JACC Cardiovasc Interv. 2020;13:1071–1082. https://​doi.​org/​10.​1016/​j.​jcin.​2019.​12.​026.
26.
Zurück zum Zitat Grubb K. Early OPTIMIZE PRO Data for Evolut Pro TAVR Systems Presentation. Society for Cardiovascular Angiography and Interventions. SCAI Virtual Sci Sessions. 2021. Grubb K. Early OPTIMIZE PRO Data for Evolut Pro TAVR Systems Presentation. Society for Cardiovascular Angiography and Interventions. SCAI Virtual Sci Sessions. 2021.
27.
Zurück zum Zitat Lefèvre G, Jégou A, Dambrin G, Picard F, Anconina J, Pouzet B, et al. Comparison of TransFemoral Transcatheter Aortic Valve Replacement Performed With a Minimally Invasive Simplified Technique: "FAST" Versus a Standard Approach. J Invasive Cardiol. 2019;31:300–306. Lefèvre G, Jégou A, Dambrin G, Picard F, Anconina J, Pouzet B, et al. Comparison of TransFemoral Transcatheter Aortic Valve Replacement Performed With a Minimally Invasive Simplified Technique: "FAST" Versus a Standard Approach. J Invasive Cardiol. 2019;31:300–306.
28.
Zurück zum Zitat Barbanti M, van Mourik MS, Spence MS, et al. Optimising patient discharge management after transfemoral transcatheter aortic valve implantation: the multicentre European FAST-TAVI trial. EuroIntervention. 2019;15:147–54.CrossRef Barbanti M, van Mourik MS, Spence MS, et al. Optimising patient discharge management after transfemoral transcatheter aortic valve implantation: the multicentre European FAST-TAVI trial. EuroIntervention. 2019;15:147–54.CrossRef
29.
Zurück zum Zitat Ichibori Y, Li J, Davis A, et al. Feasibility and safety of adopting next-day discharge as first-line option after transfemoral transcatheter aortic valve replacement. J Invasive Cardiol. 2019;31:64–72.PubMed Ichibori Y, Li J, Davis A, et al. Feasibility and safety of adopting next-day discharge as first-line option after transfemoral transcatheter aortic valve replacement. J Invasive Cardiol. 2019;31:64–72.PubMed
31.
Zurück zum Zitat Oguri A, Yamamoto M, Mouillet G, Gilard M, Laskar M, Eltchaninoff H, et al. FRANCE 2 Registry Investigators. Clinical outcomes and safety of transfemoral aortic valve implantation under general versus local anesthesia: subanalysis of the French Aortic National CoreValve and Edwards 2 registry. Circ Cardiovasc Interv. 2014;7:602–10. https://doi.org/10.1161/CIRCINTERVENTIONS.113.000403. Oguri A, Yamamoto M, Mouillet G, Gilard M, Laskar M, Eltchaninoff H, et al. FRANCE 2 Registry Investigators. Clinical outcomes and safety of transfemoral aortic valve implantation under general versus local anesthesia: subanalysis of the French Aortic National CoreValve and Edwards 2 registry. Circ Cardiovasc Interv. 2014;7:602–10. https://​doi.​org/​10.​1161/​CIRCINTERVENTION​S.​113.​000403.
34.
Zurück zum Zitat Babaliaros V, Devireddy C, Lerakis S, et al. Comparison of transfemoral transcatheter aortic valve replacement performed in the catheterization laboratory (minimalist approach) versus hybrid operating room (standard approach): outcomes and cost analysis. JACC Cardiovasc Interv. 2014;7:898–904.CrossRef Babaliaros V, Devireddy C, Lerakis S, et al. Comparison of transfemoral transcatheter aortic valve replacement performed in the catheterization laboratory (minimalist approach) versus hybrid operating room (standard approach): outcomes and cost analysis. JACC Cardiovasc Interv. 2014;7:898–904.CrossRef
38.
Zurück zum Zitat • Baron SJ, Wang K, House JA, Magnuson EA, Reynolds MR, Makkar R, et al. Cost-Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Risk. Circulation. 2019;139:877–888. https://doi.org/10.1161/CIRCULATIONAHA.118.035236. This cost analysis study revealed that from a resource utilization and cost perspective, minimalist TAVR uses significantly less resources compared to traditional approaches. • Baron SJ, Wang K, House JA, Magnuson EA, Reynolds MR, Makkar R, et al. Cost-Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Risk. Circulation. 2019;139:877–888. https://​doi.​org/​10.​1161/​CIRCULATIONAHA.​118.​035236. This cost analysis study revealed that from a resource utilization and cost perspective, minimalist TAVR uses significantly less resources compared to traditional approaches.
39.
Zurück zum Zitat Cohen DJ. Economic outcomes of TAVR vs. SAVR for low-risk patients: results from the PARTNER 3 trial. TCT. 2021. Cohen DJ. Economic outcomes of TAVR vs. SAVR for low-risk patients: results from the PARTNER 3 trial. TCT. 2021.
40.
Zurück zum Zitat Lampert J, Finn MT, Kantor A, Akkoc D, Chen S, Brandwein R, et al. Urologic Complications in Patients Receiving Indwelling Urinary Catheters During Transcatheter Aortic Valve Replacement. J Invasive Cardiol. 2020;32(7):269–74 (PMID: 32610268).PubMed Lampert J, Finn MT, Kantor A, Akkoc D, Chen S, Brandwein R, et al. Urologic Complications in Patients Receiving Indwelling Urinary Catheters During Transcatheter Aortic Valve Replacement. J Invasive Cardiol. 2020;32(7):269–74 (PMID: 32610268).PubMed
Metadaten
Titel
Update on Minimalist TAVR Care Pathways: Approaches to Care in 2022
verfasst von
Mariem A. Sawan
Avery E. Calhoun
Kendra J. Grubb
Chandan M. Devireddy
Publikationsdatum
29.06.2022
Verlag
Springer US
Erschienen in
Current Cardiology Reports / Ausgabe 9/2022
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-022-01737-x

Weitere Artikel der Ausgabe 9/2022

Current Cardiology Reports 9/2022 Zur Ausgabe

Global Cardiovascular Health (L Sperling and D Gaita, Section Editors)

Health Disparities Across the Continuum of ASCVD Risk

Diabetes and Cardiovascular Disease (D Bruemmer, Section Editor)

Closed-Loop Artificial Pancreas Therapy for Type 1 Diabetes

Interventional Cardiology (SR Bailey and T Helmy, Section Editor)

Tricuspid Valve Percutaneous Therapies

Lipid Abnormalities and Cardiovascular Prevention (ED Michos, Section Editor)

Keto is Trending: Implications for Body Weight and Lipid Management

Women and Cardiovascular Health (N Goldberg and S Lewis, Section Editors)

Racial Disparities in Cardiovascular Risk and Cardiovascular Care in Women

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Komplette Revaskularisation bei Infarkt: Neue Studie setzt ein Fragezeichen

24.04.2024 ACC 2024 Nachrichten

Eine FFR-gesteuerte komplette Revaskularisation war in einer Studie bei Patienten mit akutem Myokardinfarkt und koronarer Mehrgefäßerkrankung klinisch nicht wirksamer als eine alleinige Revaskularisation der Infarktarterie.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.